15-Sep-2015, Spontaneous, Patient/Consumer Serious report (Report duplicates -  Sanofi: 1-757607968)
A Female patient received COPAXONE (GLATIRAMER ACETATE, Product is or cannot be excluded as a Teva 
product).
The patient took COPAXONE for MULTIPLE SCLEROSIS (GLATIRAMER ACETATE, Injection, Unknown dose 
strength).
While on the suspect medication(s), the patient experienced POSITIVE FOR JCV(Serious ); DEPRESSION(Not 
Serious ); SHINGLES(Not Serious ); RASH(Not Serious ) . 
This female patient reported while on Copaxone had to do the injections every other day because she had a rash 
and depression. She reported had outbreak of shingles over 20 times that lasts 3 - 4 weeks; her doctor prescribed 
Zovirax 3 - 4 weeks. The patient reports tested positive for JCV.
At the time of the report the outcome of the AEs were:   POSITIVE FOR JCV : Unknown,   DEPRESSION : 
Unknown,   SHINGLES : Unknown,   RASH : Unknown.
Action taken with suspect drugs: COPAXONE - Unknown.
The patient had medical history of MS(Continuing).
The patient's concomitant medication were unspecified.
The patient's past medication were unspecified.
Lab tests JC Virus: positive 
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))
Teva Comment:  POSITIVE FOR JCV is not related to GLATIRAMER ACETATE, possibly intercurrent otherwise 
aquired infection. 
Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.